Xinhong Wu

机构：Hubei Cancer Hospital · ORCID：0000-0002-7544-5544

发表论文 77 篇 · 总被引 1293 次 · h-index 17

代表论文

• Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2–Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2–Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial (2024 · Journal of Clinical Oncology · 被引 47)
• Advances in novel cell death mechanisms in breast cancer: intersecting perspectives on ferroptosis, cuproptosis, disulfidptosis, and pyroptosis (2025 · Molecular Cancer · 被引 30)
• Metronomic Capecitabine Plus Aromatase Inhibitor as Initial Therapy in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: The Phase III MECCA Trial (2025 · Journal of Clinical Oncology · 被引 12)
• Comparison of nipple sparing and skin sparing mastectomy with immediate reconstruction based on patient reported outcomes (2025 · Scientific Reports · 被引 9)
• Bireociclib plus fulvestrant for HR+/HER2- advanced female breast cancer progressed on or after endocrine therapy: phase 3 BRIGHT-2 study interim analysis (2025 · Nature Communications · 被引 5)
• An open‐label, single‐arm, multicenter, phase II trial of bireociclib as monotherapy for heavily pretreated HR‐positive, HER2‐negative advanced breast cancer patients: BRIGHT‐1 trial (2025 · 癌症：英文版 · 被引 5)